Join the ME SUD Learning Community for the April 2, 2025 presentation OD Prevention, part of the RX ECHO: SUD Through a Pharmacy Lens. Presented by Stephanie Nichols, PharmD, BCCP, MPH. PowerPoint Presentation Podcast
RX ECHO: SUD Through a Pharmacy Lens | OD Prevention Read More »
The ME SUD Learning Community hosted the didactic on October 10th, 2024, “Project ECHO: Methadone in the Age of Fentanyl: Transitions in Methadone and Buprenorphine” presented by Stephanie Nichols, PharmD, BCPP, MPH.
Project ECHO: Methadone in the Age of Fentanyl: Drug Interactions with Methadone Read More »
The ME SUD Learning Community hosted the didactic on October 10th, 2024, “Project ECHO: Methadone in the Age of Fentanyl: Transitions in Methadone and Buprenorphine,” presented by Stephanie Nichols, PharmD, BCPP, MPH.
122 | Project ECHO: Methadone in the Age of Fentanyl | Drug Interactions with Methadone Read More »
Prescribing buprenorphine: What is the role and risk of monoproduct? Andrea Truncali, MD MPH & Stephanie Nichols, PharmD, MPH, BCPP, FCCP Developed with Support of the Maine Substance Use Disorder Learning Collaborative March 2024 Key Buprenorphine (both combo and mono) = buprenorphine Buprenorphine monoproduct = BUP, mono Buprenorphine/naloxone = BUP-N, combo
March 2024 – Journal Club- Prescribing buprenorphine: What is the role and risk? Read More »
October 4, 2022 | Sephanie Nichols, PharmD MPH and Eric Haram, LADC
Objectives:
Understand prescribing and treatment for Alcohol Use Disorder
Describe ways to engage with patients when discussing unexpected information
Medications and Treatment for Alcohol Use Disorder Read More »
August 9, 2022 | Stephanie Nichols, PharmD, BCPS, BCPP, FCCP
This session will review the interface and nuances of the use of buprenorphine in a person with pain. We will review multiple angles, including both the treatment of acute and chronic pain in a person receiving buprenorphine for OUD and the use of buprenorphine to treat pain (with or without OUD).
Learning objectives:
Compare and contrast the various formulations of buprenorphine including consideration of FDA indication, route of administration, and dose
Identify the clinical result of using buprenorphine in a person who is opioid naive and in a person who is currently using other medical or nonmedical opioids
Describe the efficacy and clinical pearls associated with the use of buprenorphine patch and transmucosal forms for analgesia in a person with and without OUD
Identify emerging and best practices regarding treatment of acute and chronic pain in a person receiving buprenorphine for OUD
Buprenorphine and Pain Read More »
June 14, 2022 | Stephanie Nichols, PharmD, BCPS, BCPP
This session will review the initiation of buprenorphine for OUD using the microdosing and macrodosing approaches. We will review why these emerging approaches are preferable to traditional approaches, the supporting evidence, and the practical pearls for implementation.
Learning Objectives:
Describe microdosing and macrodosing approaches to buprenorphine initiation
Recall the evidence supporting each of these approaches
Discuss practical pearls regarding these approaches when applied to patient care
New Strategies to Initiate Buprenorphine Therapy: Microdosing and Macrodosing Read More »
